Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments

References

• Rook's Textbook of Dermatology ninth edition 2016. 9 ed: Wiley-Blackwell; 2016.
   Google Scholar
• NICE. Psoriasis: assessment and management Clinical guideline [CG153]. 2012. [cited 2017 Feb 28]. https://www.nice.org.uk/guidance/cg153/chapter/5-Other-versions-of-this-guideline - full-guideline
   Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924–926.
   PubMed Web of Science ®Google Scholar
• Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183:269–274.
   PubMedGoogle Scholar
• Zweegers J, de Jong EM, Nijsten TE, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. Dermatol Online J. 2014;20:1–9.
   Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–2294.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304:87–113.
   PubMed Web of Science ®Google Scholar
• Zachariae H, Zachariae R, Blomqvist K, et al. Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study. Acta Derm Venereol. 2001;81:116–121.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Gniadecki R, Mork NJ, et al. Implementing best practice in psoriasis: a Nordic expert group consensus. Acta Derm Venereol. 2014;94:547–552.
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299:111–138.
   PubMed Web of Science ®Google Scholar
• SIGN. SIGN GUIDELINE 121: DIAGNOSIS AND MANAGEMENT OF PSORIASIS AND PSORIATIC ARTHRITIS IN ADULTS. [cited 2017 Feb 28]. http://sign.ac.uk/guidelines/fulltext/121/section5.html
   Google Scholar
• Raboobee N, Aboobaker J, Jordaan HF, et al. Guideline on the management of psoriasis in South Africa. S Afr Med J. 2010;100:257–282.
   PubMedGoogle Scholar
• Clinical Practice Guidelines: Management of Psoriasis Vulgaris. In: (MaHTAS) MHTAS, Medical Development Division MoHM, Level 4 BE, Precinct 1, Centre FGA, 62590 P, Malaysia, editors; 2013.
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–485.
   PubMed Web of Science ®Google Scholar
• Canadian Psoriasis Guidelines Addendum C. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg. 2016;20:375–431.
   PubMed Web of Science ®Google Scholar
• Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351–364.
   PubMed Web of Science ®Google Scholar
• Bruner CR, Feldman SR, Ventrapragada M, et al. Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003;9:2.
   PubMedGoogle Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48–54.
   PubMed Web of Science ®Google Scholar
• Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol. 2006;45:970–975.
   PubMed Web of Science ®Google Scholar
• Benoit S, Hamm H. Childhood psoriasis. Clin Dermatol. 2007;25:555–562.
   PubMed Web of Science ®Google Scholar
• Coffey J, Landells I. Topical treatment of psoriasis in children. Skin Therapy Lett. 2002;7:4–7.
   PubMedGoogle Scholar
• Al Hammadi A, Al-Haddab M, Sasseville D. Dermatologic treatment during pregnancy: practical overview. J Cutan Med Surg. 2006;10:183–192.
   PubMed Web of Science ®Google Scholar
• Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197–203.
   PubMed Web of Science ®Google Scholar
• Oren D, Nulman I, Makhija M, et al. Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk?. Can Fam Physician. 2004;50:1083–1085.
   PubMed Web of Science ®Google Scholar
• Tauscher AE, Fleischer AB Jr., Phelps KC, et al. Psoriasis and pregnancy. J Cutan Med Surg. 2002;6:561–570.
   PubMed Web of Science ®Google Scholar
• Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol. 2005;15:37–39.
   PubMed Web of Science ®Google Scholar
• Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol. 2006;142:1138–1143.
   PubMedGoogle Scholar
• Piraccini BM, Tosti A, Iorizzo M, et al. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol. 2001;144:1000–1005.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol. 2007;87:167–168.
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139:655–659.
   PubMed Web of Science ®Google Scholar
• Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68:355–358.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15. quiz 6-8.
   PubMed Web of Science ®Google Scholar
• Morman MR. Possible side effects of topical steroids. Am Fam Physician. 1981;23:171–174.
   PubMed Web of Science ®Google Scholar
• Prawer SE, Katz HI. Guidelines for using superpotent topical steroids. Am Fam Physician. 1990;41:1531–1538.
   PubMed Web of Science ®Google Scholar
• Roeder A, Schaller M, Schafer-Korting M, et al. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol. 2005;18:3–11.
   PubMed Web of Science ®Google Scholar
• du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111:581–583.
   PubMed Web of Science ®Google Scholar
• Requena L, Zamora E, Martin L. Acroatrophy secondary to long-standing applications of topical steroids. Arch Dermatol. 1990;126:1013–1014.
   PubMedGoogle Scholar
• Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica. 1990;181:51–53.
   PubMedGoogle Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1–27.
   PubMed Web of Science ®Google Scholar
• van der Vleuten CJ, van Vlijmen-Willems IM, de Jong EM, et al. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res. 1999;291:390–395.
   PubMed Web of Science ®Google Scholar
• Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54:148–154.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology (Basel). 2000;200:292–298.
   PubMed Web of Science ®Google Scholar